CA2381095C - Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique - Google Patents
Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique Download PDFInfo
- Publication number
- CA2381095C CA2381095C CA2381095A CA2381095A CA2381095C CA 2381095 C CA2381095 C CA 2381095C CA 2381095 A CA2381095 A CA 2381095A CA 2381095 A CA2381095 A CA 2381095A CA 2381095 C CA2381095 C CA 2381095C
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- compound
- rist
- nitric oxide
- insulin resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un procédé permettant d'augmenter la sensibilité insulinique par une administration d'une quantité efficace d'un composé destiné à stimuler la production de monoxyde d'azote dans le foie. Cette invention concerne également une composition pharmaceutique renfermant une quantité efficace d'un composé destiné à stimuler la production de monoxyde d'azote dans le foie, ainsi qu'un excipient pharmaceutiquement acceptable.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10317098P | 1998-10-06 | 1998-10-06 | |
| US60/103,170 | 1998-10-06 | ||
| PCT/US1999/023098 WO2000019992A1 (fr) | 1998-10-06 | 1999-10-05 | Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2381095A1 CA2381095A1 (fr) | 2000-04-13 |
| CA2381095C true CA2381095C (fr) | 2012-08-14 |
Family
ID=22293754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2381095A Expired - Lifetime CA2381095C (fr) | 1998-10-06 | 1999-10-05 | Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1126831A4 (fr) |
| CA (1) | CA2381095C (fr) |
| WO (1) | WO2000019992A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003061639A2 (fr) | 2002-01-25 | 2003-07-31 | Diamedica Inc. | Utilisation de composes stimulant la synthese du glutathion dans la reduction de la resistance a l'insuline |
| US8673964B2 (en) | 2004-05-20 | 2014-03-18 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| JP6441679B2 (ja) | 2011-12-09 | 2018-12-19 | メタベンション インコーポレイテッド | 肝臓系の治療的な神経調節 |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
| WO2014197625A1 (fr) | 2013-06-05 | 2014-12-11 | Metavention, Inc. | Modulation de fibres nerveuses ciblées |
| US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
| AU2018230478A1 (en) | 2017-03-09 | 2019-09-12 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| GB9510037D0 (en) * | 1995-05-18 | 1995-07-12 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
-
1999
- 1999-10-05 CA CA2381095A patent/CA2381095C/fr not_active Expired - Lifetime
- 1999-10-05 WO PCT/US1999/023098 patent/WO2000019992A1/fr active Application Filing
- 1999-10-05 EP EP99951765A patent/EP1126831A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2381095A1 (fr) | 2000-04-13 |
| EP1126831A1 (fr) | 2001-08-29 |
| EP1126831A4 (fr) | 2004-10-06 |
| WO2000019992A1 (fr) | 2000-04-13 |
| WO2000019992A9 (fr) | 2000-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2641815C (fr) | Procede de traitement de la dystrophie musculaire | |
| WHITE et al. | Experimental study on the genesis of cerebral vasospasm | |
| US6147060A (en) | Treatment of carcinomas using squalamine in combination with other anti-cancer agents | |
| AU2003201577B2 (en) | Use of phosphodiesterase antagonists to treat insulin resistance | |
| Pettinger et al. | Altered renin release and propranolol potentiation of vasodilatory drug hypotension. | |
| Spielman et al. | Blockade of postocclusive renal vasoconstriction by an angiotensin II antagonists: evidence for an angiotensin-adenosine interaction | |
| Shah et al. | Persistent hyperinsulinaemic hypoglycaemia in infancy | |
| Hollister | The effect of adrenergic blocking agents (including chlorpromazine) on serum lipid levels of patients with disorders of fat metabolism | |
| AU2003201577A1 (en) | Use of phosphodiesterase antagonists to treat insulin resistance | |
| EA022166B1 (ru) | Синтетические тритерпеноиды и их применение в лечении заболеваний | |
| AU2003201578B2 (en) | Use of cholinesterase antagonists to treat insulin resistance | |
| EP2240170B1 (fr) | Procédés et compositions de traitement d'hémorragie anévrysmale sous-arachnoïdienne coronarienne et artérielle | |
| AU2003201578A1 (en) | Use of cholinesterase antagonists to treat insulin resistance | |
| CA2381095C (fr) | Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique | |
| JP2010510973A (ja) | 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用 | |
| US20040151785A1 (en) | Method for treating insulin resistance through hepatic nitric oxide | |
| CA2514090C (fr) | Utilisation de composes stimulant la synthese du glutathion dans la reduction de la resistance a l'insuline | |
| Cavagnini et al. | Impairment of growth hormone and insulin secretion in hyperthyroidism | |
| AU2003201579A1 (en) | Use of glutathione synthesis stimulating compounds in reducing insulin resistance | |
| Trouve et al. | Catecholamines, cocaine toxicity, and their antidotes in the rat | |
| US20150005252A1 (en) | Combination therapy for the treatment of cancer | |
| Scherrer | Insulin and the regulation of the cardiovascular system: Role of the L-arginine nitric oxide pathway and the sympathetic nervous system | |
| US20090234150A1 (en) | Use of ppar-alpha agonists to treat skeletal muscle wasting disorders | |
| US4152425A (en) | Glucose containing infusion solution | |
| Sadri | HISS-dependent control of insulin sensitivity in health and disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20191007 |